Skip To Main Content
Tetsuyuki Igarashi on Muck Rack

Tetsuyuki Igarashi

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tetsuyuki

Contact Tetsuyuki, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net | Blood Cancer Journal

|
By Masahiro Onozawa, Takeshi Kondo, Minoru Kanaya, Fumiaki Fujii, Tetsuyuki Igarashi
| Nature Verified
Dear Editor, Acute myeloid leukemia (AML) has a median age at diagnosis of 68 years, and many patients are deemed ineligible for intensive chemotherapy or allogeneic stem cell transplantation, resulting in a generally poor prognosis [1]. The pivotal VIALE-A randomized trial showed that Azacitidine (AZA) at 75 mg/m²/day for 7 days every 28 days, combined with once-daily continuous Venetoclax (VEN) at 400 mg for 28 days, significantly improved composite complete remission (CRc) rates (66.4% vs.
Open in Who Shared Issue with article?
See all 1 articles